KWA
STLN

Kingswood Wealth Advisors’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Kingswood Wealth Advisors’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$662K Buy
121,900
+18,700
+18% +$78.5K 0.03% 528
2026
Q1 		$317K Buy
103,200
+4,500
+5% +$13.8K 0.02% 691
2025
Q4 		$351K Buy
98,700
+21,100
+27% +$78.3K 0.02% 628
2025
Q3 		$271K Buy
77,600
+13,200
+20% +$45.2K 0.02% 662
2025
Q2 		$132K Buy
+64,400
New +$161K 0.01% 725

Other funds holding STLN

Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IAAG
Innovative Asset Advisors Group Shelton, Connecticut $229M AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Kingswood Wealth Advisors's STLN Position: Q2 2026 in Review

Kingswood Wealth Advisors increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 18% in Q2 2026, buying an estimated $78.5K and bringing the position to 121,900 shares worth $662K. The position accounts for 0.03% of the portfolio, ranked #528.

Kingswood Wealth Advisors first reported a position in STLN in Q2 2025 and has held it in 5 quarters since. 29 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Kingswood Wealth Advisors held 121,900 shares of Starling Oncology Institute, Inc. Common Stock worth $662K as of Q2 2026.
  • Kingswood Wealth Advisors bought 18,700 Starling Oncology Institute, Inc. Common Stock shares in Q2 2026, an estimated $78.5K.
  • Starling Oncology Institute, Inc. Common Stock made up 0.03% of Kingswood Wealth Advisors's portfolio in Q2 2026, its #528 holding.
  • Kingswood Wealth Advisors first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2025 and has held it in 5 quarters since.
  • 29 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2026.

Based on Kingswood Wealth Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.